PLX Protalix BioTherapeutics Inc. (DE)

0.48
+0.03  (+6%)
Previous Close 0.45
Open 0.45
Price To Book -1.09
Market Cap 71219962
Shares 148,374,921
Volume 613,852
Short Ratio 5.7
Av. Daily Volume 660,856

NewsSee all news

  1. The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut
  2. Protalix BioTherapeutics Presents Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposium™ 2019
  3. The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs
  4. New Research: Key Drivers of Growth for Voya Financial, Conduent, Milacron, Altair Engineering, Genesis Healthcare, and Protalix BioTherapeutics — Factors of Influence, Major Initiatives and Sustained Production
  5. Protalix BioTherapeutics to Present Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposium™ 2019

SEC filingsSee all SEC filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19590513
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19590200
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19579458
  4. 8-K - Current report 19566182
  5. 8-K - Current report 19520310

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved May 1, 2012.
Taliglucerase alfa
Gaucher disease
Phase 3 dosing commenced October 2016. Enrollment to be finalized 2018.
Pegunigalsidase alfa (PRX-102)
Fabry disease
Phase 2 interim data released January 3, 2017. Full data released April 12, 2017. Company noted data were positive but results showed efficacy down on January data.
AIR DNase (PRX-110)
Cystic Fibrosis
Phase 2 data released March 13, 2018 - key endpoints met. Data presented at DDW Meeting - 67% of patients experienced a clinical response.
OPRX-106
Ulcerative Colitis
Phase 3 completion of enrolment announced December 17, 2018 with additional data due 2019.
Pegunigalsidase alfa (PRX-102) BRIDGE
Fabry disease
Phase 3 PK data from open label trial to be presented at WORLDSymposium February 7, 2019.
Pegunigalsidase alfa (PRX-102)
Fabry disease

Latest News

  1. The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut
  2. Protalix BioTherapeutics Presents Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposium™ 2019
  3. The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs
  4. New Research: Key Drivers of Growth for Voya Financial, Conduent, Milacron, Altair Engineering, Genesis Healthcare, and Protalix BioTherapeutics — Factors of Influence, Major Initiatives and Sustained Production
  5. Protalix BioTherapeutics to Present Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposium™ 2019
  6. Does The Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Share Price Tend To Follow The Market?
  7. Implied Volatility Surging for Protalix (PLX) Stock Options
  8. Moving Average Crossover Alert: Protalix BioTherapeutics
  9. Protalix BioTherapeutics Announces the Completion of Enrollment in the Phase III BRIDGE Clinical Trial of pegunigalsidase alfa for the Treatment of Fabry Disease
  10. Protalix (PLX) Reports Q3 Loss, Lags Revenue Estimates
  11. Protalix: 3Q Earnings Snapshot
  12. Will Protalix (PLX) Report Negative Earnings Next Week? What You Should Know
  13. The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker
  14. The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs
  15. Today’s Research Reports on Stocks to Watch: GTx and Protalix BioTherapeutics

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19590513
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19590200
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19579458
  4. 8-K - Current report 19566182
  5. 8-K - Current report 19520310
  6. 8-K - Current report 19510480
  7. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 181242189
  8. 8-K - Current report 181237010
  9. 8-K - Current report 181233586
  10. CT ORDER - Confidential treatment order 181215692